KRAS has the distinction of being a preeminent oncoprotein as it is mutated in more than 85% of RAS-altered cancers. The RAS (G12D Mutant) antibody [HL10] is the first commercially available recombinant antibody that demonstrates exceptional specificity by paraffin-embedded immunohistochemistry and western blot for the RAS G12D mutant protein.
*Optimal dilutions/concentrations should be determined by the researcher.
Suggest using high sensitivity ECL for optimization. GTX14698 Trident femto Western HRP Substrate is recommended.
Not tested in other applications.
293T transfected NRAS(G12D) , AsPC1 , HPAC , HPAF-II , PANC1 , SU86.86
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
1.5 mg/ml (Please refer to the vial label for the specific concentration.)
Carrier-protein conjugated synthetic peptide surrounding mutant G12D of human K-Ras. The exact sequence is proprietary.
Affinity purified by Protein A.
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.